Last reviewed · How we verify
NCT04903665
PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I
trial testing Multi-cancer early detection test in Gynecologic Cancer in 495 participants. Status unknown.
22 August 2022
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 495 |
| Start date | 11 February 2021 |
| Primary completion | 22 August 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Multi-cancer early detection test
Conditions studied
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
Sponsor
Fudan University
Who can join
18 and older, female only, with Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective study aimed to develop and validate the performance of combined multi-omitcs assays for early detection of gynecologic cancers. Biomarkers of cfDNA methylation, ctDNA mutation and blood miRNA markers will be evaluated. The study will enroll approximately 495 female participants, including participants with gynecologic cancers or benign diseases.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027 -
Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine.
Bamodu OA, Chung CC, Pisanic TR. · · 2023 · cited 13× · PMID 40028482 · DOI 10.1016/j.jlb.2023.100126 -
Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review.
Ranganathan K, Kurian NS, Goswami HM, Rishi KD, et al · · 2024 · cited 5× · PMID 40027943 · DOI 10.1016/j.jlb.2024.100150 -
Performance of Liquid Biopsy-Based Multi-Omics Biomarkers for Early Detection of Gynecological Malignancies: A Prospective Study (PERCEIVE-I).
Feng Z, Ge H, Wang J, Wang Y, et al · · 2025 · cited 3× · PMID 40178300 · DOI 10.1002/advs.202401760 -
Multicancer Early Detection Tests: A State-of-the-Art Review for Otolaryngologists.
Kennedy E, Durm G, Farlow JL. · · 2024 · cited 2× · PMID 39463807 · DOI 10.1002/oto2.70040
Verify or expand the search:
- PubMed search for NCT04903665
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Multi-cancer early detection test
Trials testing the same drug.
- NCT05874648 — PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection · unknown
- NCT04972201 — A Proof of Concept Study of Pan-cancer Early Detection by Liquid Biopsy · completed
- NCT04820868 — The Unintrusive Detection of EaRly-stage Cancers · completed
- NCT04817306 — Pan-canceR Early DetectIon projeCT (PREDICT) · unknown
- NCT04822792 — Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT · unknown
Other recruiting trials for Gynecologic Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
- NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
- NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04903665 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 28 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04903665.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing